HIV coinfection predicts failure of ledipasvir/sofosbuvir in treatment-naïve noncirrhotic patients with HCV genotype

Biblos-e Archivo/Manakin Repository

Show simple item record

dc.contributor.author Berenguer, Juan
dc.contributor.author Calleja, José Luis
dc.contributor.author Montes, María Luisa
dc.contributor.author Gil, Ángela
dc.contributor.author Moreno, Ana
dc.contributor.author Bañares, Rafael
dc.contributor.author Aldámiz-Echevarría, Teresa
dc.contributor.author Albillos, Agustín
dc.contributor.author Téllez, María Jesús
dc.contributor.author Olveira, Antonio
dc.contributor.author Domínguez, Lourdes
dc.contributor.author Fernández, Inmaculada
dc.contributor.author García-Samaniego, Javier
dc.contributor.author Polo, Benjamín A.
dc.contributor.author Álvarez, Beatriz
dc.contributor.author Ryan, Pablo
dc.contributor.author Barrio, José
dc.contributor.author Devesa, María J.
dc.contributor.author Benítez, Laura
dc.contributor.author Santos, Ignacio
dc.contributor.author Buey, Luisa García
dc.contributor.author Sanz, José
dc.contributor.author Poves, Elvira
dc.contributor.author Losa, Juan E.
dc.contributor.author Fernández-Rodríguez, Conrado
dc.contributor.author Jarrín, Inmaculada
dc.contributor.author Calvo, María J.
dc.contributor.author González-García, Juan
dc.contributor.other UAM. Departamento de Medicina es_ES
dc.contributor.other Instituto de Investigación Sanitaria Hospital Universitario de La Paz (IdiPAZ) es_ES
dc.date.accessioned 2019-11-05T18:12:16Z
dc.date.available 2019-11-05T18:12:16Z
dc.date.issued 2019-05-01
dc.identifier.citation Open Forum Infectious Diseases 6.5 (2019): 1-10 en_US
dc.identifier.issn 2328-8957 es_ES
dc.identifier.uri http://hdl.handle.net/10486/689124
dc.description.abstract The efficacy of licensed direct-acting antiviral (DAA) regimens is assumed to be the same for hepatitis C virus (HCV)–monoinfected patients (HCV-Mono) and HIV/HCV-coinfected patients (HCV-Co). However, the high sustained viral response (SVR) rates of DAA regimens and the small number of HIV-infected patients included in registration trials have made it difficult to identify predictors of treatment failure, including the presence of HIV. Methods. We compared treatment outcomes for ledipasvir/sofosbuvir (LDV/SOF) against HCV G1 in treatment-naïve HCV-Mono and HCV-Co without cirrhosis in a prospective registry of individuals receiving DAAs for HCV. Results. Up to September 2017, a total of 17 269 patients were registered, and 1358 patients (1055 HCV-Mono/303 HCV-Co) met the inclusion criteria. Significant differences between HCV-Mono and HCV-Co were observed for age, gender, and G1 subtype distribution. Among HCV-Co, 99.0% were receiving antiretroviral therapy. SVR rates for LDV/SOF at 8 weeks did not differ significantly between HCV-Mono and HCV-Co (96.9% vs 94.0%; P = .199). However, the SVR rate for LDV/SOF at 12 weeks was significantly higher for HCV-Mono than HCV-Co (97.2% vs 91.8%; P = .001). A multivariable logistic regression model including age, sex, liver stiffness, G1 subtype, HCV-RNA, HIV, and treatment duration showed the factors associated with treatment failure to be male sex (adjusted odds ratio [aOR], 2.49; 95% confidence interval [CI], 1.27–4.91; P = .008) and HIV infection (aOR, 2.23; 95% CI, 1.13–4.38; P = .020). Conclusions. The results of this large prospective study analyzing outcomes for LDV/SOF against HCV G1 in treatment-naïve noncirrhotic patients suggest that HIV infection is a predictor of treatment failure in patients with chronic hepatitis C. en_US
dc.description.sponsorship This work was supported by the Spanish AIDS Research Network (RD16/0025/0017), which is included in the Spanish I+D+I Plan and is co-financed by ISCIII-Subdirección General de Evaluacion and European Funding for Regional Development (FEDER), and the Fondo de Investigación de Sanidad en España (FIS)/Instituto de Salud Carlos III (Spanish Health Research Funds; PI17/00657). en_US
dc.format.extent 10 pag. es_ES
dc.format.mimetype application/pdf en
dc.language.iso eng en
dc.publisher Oxford University Press on behalf of Infectious Diseases Society of America en_US
dc.relation.ispartof Open Forum Infectious Diseases en_US
dc.rights © The Author(s) 2019. Published by Oxford University Press on behalf of Infectious Diseases Society of America. Background. en_US
dc.subject.other Antiviral agents/administration & dosage/*therapeutic use en_US
dc.subject.other DAA en_US
dc.subject.other Hepatitis C, chronic/*complications/*drug therapy en_US
dc.subject.other HIV infections/*complications en_US
dc.subject.other Sustained virologic response en_US
dc.title HIV coinfection predicts failure of ledipasvir/sofosbuvir in treatment-naïve noncirrhotic patients with HCV genotype en_US
dc.type article en
dc.subject.eciencia Medicina es_ES
dc.relation.publisherversion https://doi.org/0.1093/ofid/ofz214 es_ES
dc.identifier.doi 10.1093/ofid/ofz214 es_ES
dc.identifier.publicationfirstpage 1 es_ES
dc.identifier.publicationissue 5 es_ES
dc.identifier.publicationlastpage 10 es_ES
dc.identifier.publicationvolume 6 es_ES
dc.relation.projectID Gobierno de España. RD16/0025/0017 es_ES
dc.relation.projectID Gobierno de España. PI17/00657 es_ES
dc.type.version info:eu-repo/semantics/publishedVersion en
dc.rights.cc Reconocimiento – NoComercial – SinObraDerivada es_ES
dc.rights.accessRights openAccess en
dc.authorUAM Calleja Panero, José Luis (101541)
dc.authorUAM González García, Juan Julián (258399)


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record